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ABSTRACT
Human dipeptidyl peptidase III (hDPP III) is a zinc-exopeptidase of the family M49 involved in final steps
of intracellular protein degradation and in cytoprotective pathway Keap1-Nrf2. Biochemical and struc-
tural properties of this enzyme have been extensively investigated, but the knowledge on its contacts
with other proteins is scarce. Previously, polypeptide aprotinin was shown to be a competitive inhibitor
of hDPP III hydrolytic activity. In this study, aprotinin was first investigated as a potential substrate of
hDPP III, but no degradation products were demonstrated by MALDI-TOF mass spectrometry.
Subsequently, molecular details of the protein–protein interaction between aprotinin and hDPP III were
studied by molecular modeling. Docking and long molecular dynamics (MD) simulations have shown
that aprotinin interacts by its canonical binding epitope with the substrate binding cleft of hDPP III.
Thereby, free N-terminus of aprotinin is distant from the active-site zinc. Enzyme-inhibitor complex is sta-
bilized by intermolecular hydrogen bonding network, electrostatic and hydrophobic interactions which
mostly involve constituent amino acid residues of the hDPP III substrate binding subsites S1, S1’, S2, S2’
and S3’. This is the first study that gives insight into aprotinin binding to a metallopeptidase.
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1. Introduction
Dipeptidyl peptidase III (DPP III) is a metallopeptidase of the
family M49 (MEROPS: https://www.ebi.ac.uk/merops/; Rawlings
et al., 2018) characterized by the hexapeptide HEXXGH zinc-
binding motif (Abramic, Spoljaric, & Simaga, 2004a; Fukasawa
et al., 1998). This proteolytic enzyme is considered to participate
in post-proteasomal intracellular protein catabolism due to its
relatively broad specificity toward peptides of different compos-
ition sized 3–10 amino acids (Abramic, Zubanovic, & Vitale,
1988; Chen & Barrett, 2004). DPP III catalyzes the hydrolysis of
penultimate peptide bond, liberating the dipeptides sequen-
tially from the N-termini of its substrates. Human DPP III is the
best characterized member of the family, in terms of biochemis-
try, structural biology and computational dynamics (Abramic
et al., 1988, 2004b; Agic et al., 2017; Barsun, Jajcanin, Vukelic,
Spoljaric, & Abramic, 2007; Bezerra et al., 2012; Chen & Barrett,
2004; Karacic, Spoljaric, Rozman, & Abramic, 2012; Kumar et al.,
2016; Shimamori, Watanabe, & Fujimoto, 1986; Tomic, Gonzalez,
& Tomic, 2012; Tomic & Tomic, 2014; Tomic, Kovacevic, &
Tomic, 2016). It is a monomeric acidic protein (pI4.6) with 737
amino acids in the polypeptide chain and molecular mass of 82
500Da (Abramic et al., 1988, 2000; Chen & Barrett, 2004). Crystal
structure of ligand-free human DPP III (PDB code: 3FVY) is very
similar to the yeast enzyme (PDB code: 3CSK) showing a two-
domain elongated protein molecule (Figure 1(A)) with a cleft
40 Å wide and 25 Å high between the lobes (Baral et al.,
2008; Bezerra et al., 2012). The X-ray structure of human dipep-
tidyl peptidase III (hDPP III) in complex with pentapeptide lig-
and revealed large domain motion upon ligand binding and
the formation of closed enzyme’s active site (Bezerra et al.,
2012). During long molecular dynamics (MD) simulations
(>100 ns) of the ligand-free hDPP III, a large-scale conform-
ational change (protein closure) has been observed (Tomic
et al., 2012.) suggesting that in solution hDPP III exists in “open”
and “closed” conformations.
In contrast to the cleavage potential of various peptides,
human DPP III has restricted action on synthetic substrates
dipeptidyl arylamides showing the preference for diarginyl ary-
lamide (Chen & Barrett, 2004; Jajcanin-Jozic & Abramic, 2013).
We have reported previously that hDPP III can act as a
post-proline cleaving enzyme on opioid tetrapeptides endo-
morphins, and that it cleaves endomorphin-1 at a compar-
able rate as serine peptidase dipeptidyl peptidase IV (DPP IV)
(Barsun et al., 2007). DPP IV has pronounced specificity for
dipeptide cleavage from the N-terminal of (poly)peptides
when proline (or alanine) is at the penultimate position
(Gabrilovac, Abramic, Uzarevic, Andreis, & Poljak, 2003). Until
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now, no polypeptide substrate of DPP III is known. However,
competitive inhibition of hDPP III with aprotinin has been
reported (Abramic, Karacic, Semanjski, Vukelic, & Jajcanin-
Jozic, 2015).
Aprotinin is monomeric, strongly basic polypeptide 58
amino acids long, derived from bovine lung tissue, also
known as bovine pancreatic trypsin inhibitor (BPTI), or basic
trypsin inhibitor of bovine pancreas (Ascenzi et al., 2003;
Mahdy & Webster, 2004). BPTI is a natural proteinase inhibi-
tor whose physiological function is to inhibit digestive protei-
nases. It is a competitive serine peptidase inhibitor of the
inhibitor family I2 (MEROPS: https://www.ebi.ac.uk/merops/).
Aprotinin inhibits chymotrypsin, plasmin, and kallikrein with
Ki in nanomolar range, and the equilibrium constant value
for the bovine trypsin-aprotinin complex is extremely low
(6 1014 M) (Fritz & Jochum, 1989). Aprotinin is used in
selected surgical interventions because it reduces hemor-
rhagic complications (Ascenzi et al., 2003). Under the trade
name Trasylol, aprotinin, as an antifibrinolytic molecule was
used as a hemostatic drug to reduce bleeding during cardiac
surgery. (Broomhead, Myers, & Mallett, 2016; Mahdy &
Webster, 2004). Clinically, aprotinin is given by continuous
infusion (Mahdy & Webster, 2004). It is metabolized in kid-
neys, where it concentrates as shown by pharmacokinetic
studies (Vio et al., 1998). The investigation on cellular distri-
bution of exogenous aprotinin in the rat kidney has shown
its distribution over the cytoplasm of the proximal tubule
cells where it remained intact for at least 24 h. Some aproti-
nin biological effects are unrelated to inhibitor function (Fritz
& Jochum, 1989). Extraordinary feature of aprotinin is its
high positive net charge at physiological pH7.4 and some of
its effects are or may be mediated by ionic interactions with
negatively charged substances or surfaces (e.g. binding to
the platelet membrane, some renal effects) (Fritz & Jochum,
1989; Vio et al., 1998).
BPTI was one of the earliest proteins whose crystal struc-
ture was solved (Deisenhofer & Steigemann, 1975; Huber,
Kukla, R€uhlmann, Epp, & Formanek, 1970). The 3-D structure
of aprotinin contains the N-terminal 310 helix, an antiparallel
b sheet, an a helix placed near the C terminus, and it is sta-
bilized by three intramolecular disulfide bonds (Figure 1(B)).
Four amino acids at the N-terminus (Arg-Pro-Asp-Phe) and
three amino acids at the C-terminus are extended from the
compact globular structure of aprotinin. It was previously
reported that a serine exopeptidase DPP IV is capable of
removing the N-terminal dipeptide of aprotinin (Nausch,
Mentlein, & Heymann, 1990).
Serine proteases and their protein inhibitors were exten-
sively studied since the balance between the proteinases
and their natural inhibitors is of great importance in biology.
Although the inhibitors differ in size and shape, they all
share the same canonical orientation of the loop binding to
the proteinase (Helland, Otlewski, Sundheim, Dadlez, &
Smalås, 1999). Numerous studies (crystallographic, thermo-
dynamic, kinetic and mutational) have been performed on
the protein inhibitor-serine proteinase interaction (cited in
Helland et al., 1999), revealing the importance of the residue
at P1 position located at center of the protein inhibitor
canonical binding loop (nomenclature as described by
Schechter & Berger, 1967). This residue is responsible for
majority (up to 50%) of all contacts between the inhibitor
and proteinase. Specificity of inhibition can be changed by a
mutation at the P1 site. For instance, replacement of Lys by
Val in aprotinin converts it from the trypsin inhibitor to the
neutrophil elastase inhibitor. Extremely strong inhibition of
various trypsins with BPTI (aprotinin; Ka in the 10
11 to 1015
M1 range) arises primarily from the interaction between the
side chain of Lys15 at the P1 position and Asp189 at the bot-
tom of the trypsin specificity pocket (Helland et al., 1999).
Crystallographic studies of bovine trypsin-BPTI (Helland et al.,
1999) and bovine chymotrypsin-BPTI complexes (Capasso,
Rizzi, Menegatti, Ascenzi, & Bolognesi, 1997) showed that 13
amino acid residues of BPTI interact with the enzyme at
<4 Å (Krowarsch, Zakrzewska, Smalas, & Otlewski, 2005). The
residues which form the binding epitope of BPTI and interact
with trypsin and chymotrypsin by non-covalent interactions
are Thr11, Gly12, Pro13, Cys14, Lys15, Ala16, Arg17, Ile18,
Ile19, Gly36, Gly37, Cys38 and Arg39. In both trypsin and
chymotrypsin complexes with aprotinin, P1 residue (Lys15)
contributes about 50% of intermolecular H-bond and van
der Waals contacts, and becomes fully buried upon com-
plex formation.
In this study, based on the known broad specificity and
post-proline activity of hDPP III, we firstly investigated, by
using sensitive matrix assisted laser desorption ionization-
time of flight mass spectrometry (MALDI-TOF MS) method-
ology, whether aprotinin is in vitro substrate of hDPP III.
Furthermore, we aimed to elucidate the molecular details of
Figure 1. Schematic representation of: (A) the 3-D structure of human DPP III
(PDB code 3FVY) and (B) the 3-D structure of aprotinin (PDB code 4PTI).
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the interaction of hDPP III with this polypeptide using
molecular modeling study.
2. Methods
2.1. Enzyme purification
Recombinant human DPP III was expressed and purified as
described by Spoljaric et al. (2011).
2.2. Peptide hydrolysis
Aprotinin (product of Bachem) degradation by purified
human DPP III was tested in reaction mixtures containing
20–300 lM aprotinin, 15mM Tris–HCl buffer pH 7.4 (with or
without 50 lM CoCl2) and 1 108 M to 9 107 M hDPP III.
To controls, instead of the enzyme, 15mM Tris–HCl was
added. After 18 h of incubation at 37 C, reaction mixtures
and controls were frozen. Subsequently, MALDI MS analysis
was performed in sample aliquots.
2.3. MALDI-TOF MS analysis
For mass spectrometry analysis, stock solutions of the control
and reaction mixture were diluted 100 times with pure
water. A solution of a-cyano-4-hydroxycinnamic acid was
prepared by dissolving 3mg of the solid compound into a
50:50 solution of acetonitrile and water containing 0.1% tri-
fluoroacetic acid (TFA). During sample preparation, 1 lL of
the diluted solution was deposited onto MALDI target plate,
each sample at the separate spot, and a 1.0lL aliquot of
MALDI matrix solution was added and the resulting droplet
was left to crystallize by air drying. Mass spectra were
acquired on a Microflex LT (Bruker Daltonik, Bremen,
Germany) MALDI-TOF mass spectrometer operated in posi-
tive linear mode.
2.4. System preparation for molecular modeling study
The crystallographically determined structures of ligand-free
human DPP III in its “open” form (PDB code 3FVY, resolution
1.9 Å) and bovine aprotinin (PDB code 4PTI, resolution 1.5 Å)
were obtained from the Protein Data Bank (https://www.rcsb.
org) and used as starting structures. Prior to docking and
MD simulations, amino acid residues missing in 3FVY,
Pro224-Asp227, were modeled using the program
Modeller9v2 (Webb & Sali, 2016). The crystallized water mole-
cules present in both structures as well as chloride and mag-
nesium ions in 3FVY were removed. All Glu and Asp residues
are negatively charged (1) and all Arg and Lys residues are
positively charged (þ1), as expected at physio-
logical conditions.
2.5. Docking
The AutoDock (AutoDock Vina version 1.1.2 plugin in the
PyMol, Schr€odinger, LLC, New York, NY, 2015) (Trott & Olson,
2009) software was used to search the best pose of aprotinin
inside the binding site of enzyme structure. The docking box
was chosen to be in the center of the gap between the two
enzyme subunits, and the size of the box was
100 100 100 Å3. The best model according to the lowest
interaction energy among the aprotinin and the residues
inside the active site of hDPP III was used as an initial point
for MD simulations.
2.6. MD simulations
Prepared hDPP III-aprotinin complex, as well as the ligand-
free hDPP III was parametrized using the ff14SB force field
(Maier et al., 2015) while for the zinc cation, Zn2þ parameters
derived in previous work were used (Tomic et al., 2012.).
Only the nonbonding parameters were used for Zn2þ ion,
namely: charge 2.0e, VdW radius 1.22 Å and VdW energy
well 0.250 kcal/mol. Histidines protonation site was deter-
mined according to their ability to form hydrogen bonds (H-
bonds) with neighboring amino acid residues. The systems
were then solvated with a truncated octahedron box of
TIP3P (Jorgensen, Chandrasekhar, Madura, Impey, & Klein,
1983) water type molecules. Besides water molecules, Naþ
ions were added to neutralize the systems and placed in the
vicinity of charged amino acids at the protein surface.
Periodic boundary conditions were used and the electrostatic
interactions were calculated using the particle-mesh Ewald
method (Darden, York, & Pedersen, 1993). The real part
Figure 2. MALDI-TOF mass spectra of the (A) control sample of a pure aproti-
nin solution and (B) reaction mixture of the aprotinin and human DPP III
enzyme. In both spectra, undigested aprotinin is present in two forms, as a sin-
gle and doubly charged ion.
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contributions to electrostatic and van der Waals interactions
were calculated within a cutoff radius of 11 Å. The solvated
systems were then minimized in three cycles with different
constraints. In the first cycle (1500 steps), water molecules
were relaxed, while protein and zinc atom were constrained
using a harmonic potential with a force constant of 32 kcal/
(mol Å2). In the second (2500 steps), and the third cycles
(1500 steps), the same constant was applied to the zinc
atom while only the protein backbone was constrained with
32 and 10 kcal/(mol Å2), respectively. The energy minimiza-
tion procedure, consisting of 470 steps of steepest descent
followed by the conjugate gradient algorithm for the remain-
ing optimization steps, was the same in all three cycles. The
minimized system was firstly heated from 0 to 300 K during
30 ps using NVT conditions and then equilibrated 300 ps dur-
ing which the initial constraints on the protein and the metal
ion were used. Finally, water density adjustment and pro-
ductive MD simulations were performed at constant tem-
perature and pressure (300 K and 1 atm) using NPT
conditions without any constraints.
The temperature was held constant using Langevin
dynamics with a collision frequency of 1 ps1. Bonds involv-
ing hydrogen atoms were constrained using the SHAKE algo-
rithm (Ryckaert, Ciccotti, & Berendsen, 1977). Simulations of
complex and ligand-free hDPP III were performed within the
program package AMBER14 (http://ambermd.org) (Case et al.,
2014). Trajectories were 200 ns long, with a time step of 1 fs,
and structures were sampled every 1 ps.
3. Results and discussion
3.1. Aprotinin interacts with, but is not degraded by
human DPP III
We have recently shown that aprotinin acts as a competitive
inhibitor of hDPP III hydrolytic activity, with a Ki value of
11.7 lM at physiological pH 7.4 (Abramic et al., 2015). To
check whether this polypeptide could be cleaved by this
enzyme, we performed long incubations with a high concen-
tration of hDPP III, followed by MALDI-MS analysis of reaction
mixture aliquots, as described in Methods. However, no
enzymatic degradation of aprotinin was observed. As shown
in Figure 2 illustrating one experiment, identical MS spectra
were obtained for the reaction mixture and control sample
without the enzyme. A major peak was observed at 6513Da,
and, at 3257Da, single peak of a doubly-charged ion. No
peak corresponding to the expected product of DPP III cata-
lyzed hydrolysis of aprotinin, N-terminal Arg-Pro dipeptide
(272Da, the range not shown in the figure) was observed.
Figure 3. Binding pose of aprotinin into the topographical surface of hDPP III obtained by molecular docking. (A) and (B), the overall structure of the hDPP III-apro-
tinin complex in two different views.
Figure 4. Overlay of the backbone atoms of the hDPP III in the complex with
aprotinin obtained by molecular docking and after 200 ns of MD simulations .
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3.2. Molecular modeling of human DPP III-aprotinin
interaction
To further investigate interaction of hDPP III with aprotinin,
we combined docking with MD simulations. Since the aproti-
nin molecule has a length of 29 Å, and a diameter of 19 Å
(Fritz & Jochum, 1989), we have used “open” (ligand-free)
form of hDPP III for docking. In contrast to the mode of
interaction with serine endopeptidases, aprotinin has been
shown to interact with the active center of DPP IV by its free
N-terminus (Arg1-Pro2 residues) (Engel et al., 2006). Since
DPP III and DPP IV are exopeptidases acting on free amino-
end of their peptide substrates, we expected similar inter-
action mode of aprotinin with hDPP III. However, the best
binding pose obtained by molecular docking revealed that
hDPP III does not bind aprotinin’s amino-end. As shown in
Figure 3(A,B), amino acid residues lining the hDPP III inter-
domain cleft make numerous H-bonds and hydrophobic
interactions with the aprotinin including canonical binding
loop (residues 13PCKAR17). At the same time, N-terminus of
aprotinin is far away (31.7 Å) from the hDPP III active-site
zinc, and together with the C-terminus extends from the
substrate binding cleft (Figure 3(B)). This is in agreement
Figure 5. Rmsd profiles of the DPP III and aprotinin backbone obtained from MD simulations of ligand-free hDPP III and hDPP III-aprotinin complex.
Figure 6. Amino acid residues of aprotinin that form hydrogen bonds with
amino acid residues from enzyme binding site are shown in the complex struc-
ture obtained after 155 ns of MD simulations. The H-bond network K46-N394-
F314 and R17-S384-E327, shown as black dashed lines, stabilizes aprotinin in
the enzyme binding site. The zinc cation is shown as a sphere. Substrate bind-
ing subsites S2, S1, S1’, S2’ and S3’ are indicated. The hydrogen atoms are not
shown for clarity.
Table 1. Populations of the selected intermolecular hydrogen bonds (HB) and
hydrophobic interactions (HI) averaged over 200 ns long MD simulations of
the hDPP III-aprotinin complex.
Aprotinin residue hDPP III residue HB (%) HI (%)
Asp3 Side Ser497 Side 7.5 –
Glu7 Side Ser500 Side – 28.5
Pro8 Side Thr501 Side – 12.2
Pro8 Main Ser504(S2) Side 1.2 –
Tyr10 Side Ser504(S2) Side – 74.9
Tyr10 Side Ala567 Side – 60.9
Gly12 Main His568 (S1’, S2’) Side 2.6 6.7
Pro13 Side Leu413 Side – 4.4
Pro13 Side Glu508 (S2, S1) Side – 1.0
Cys14 Side Ala388(S1’,S2’, S3’) Side – 35.1
Lys15 Main Ala388(S1’,S2’, S3’) Main 88.3 –
Lys15 Main Ala416(S3’) Main 5.2 –
Ala16 Side Gly385 Main – 32.1
Arg17 Side Ser101 Main 59.3 –
Arg17 Main Ser108 Side 5.7 –
Arg17 Side Phe109(S2’) Side – 41.5
Arg17 Side Ser384 Main 74.6 –
Arg17 Main Gly385 Main 75.2 –
Arg17 Side Ile386(S3’) Side – 90.7
Ile18 Side Glu316(S2) Side – 88.8
Ile18 Side Tyr318(S1, S2’) Side – 43.4
Ile18 Side Gly385 Main 1.0 64.3
Ile18 Side Pro387(S1, S1’, S2’) Side – 21.5
Ile19 Side Phe109(S2’) Side – 18.6
Ile19 Main Tyr318(S1, S2’) Side 2.5 –
Arg20 Side Glu316(S2) Side 47.8 –
Lys26 Side Asn563 Side 1.0 1.7
Gly36 Main Pro387(S1, S1’, S2’) Side 0.9 1.8
Gly36 Main Ala388(S1’,S2’, S3’) Side 3.0 –
Gly37 Main Asn391(S2) Main 8.6 –
Gly37 Main Asn391(S2) Side 7.6 –
Gly37 Main Asn406 Side 1.1 –
Cys38 Side Asn406 Side – 51.4
Arg39 Side Asp372 Main 1.7 –
Arg39 Main Asn406 Side 42.1 –
Arg42 Side Asp496(S2) Main 1.3 –
Lys46 Side Asn394(S2) Main 44.7 –
Ser47 Side Phe322 Main 11.8 –
Ser47 Side Phe322 Side – 5.8
HB were calculated with CPPTRAJ using default parameters. HB and HI with
distances below 2.5 and 3.5 Å, respectively, are listed in the table.
Corresponding hDPP III substrate binding subsites are given in brackets.
3600 D. AGIC ET AL.
with our experimental finding that aprotinin is not cleaved
with hDPP III.
In order to refine the docking result, we performed 200 ns
long MD simulations. As can be seen from Figure 4, by dock-
ing predicted binding pose is similar to that found in the
structure obtained after 200 ns of MD simulations. Moreover,
in the binding pose obtained after MD simulations aprotinin
interacts with more amino acids residues from the “upper”
and “lower” protein domain than in the binding pose
obtained by docking.
3.3. Influence of aprotinin binding on hDPP III protein
structure and zinc coordination
According to the comparison of the root mean square devi-
ation (rmsd) profiles determined by MD simulations of the
ligand-free and complexed enzyme, aprotinin binding to
hDPP III has a significant effect on protein stabilization
(Figure 5). Namely binding of aprotinin molecule deep into
the inter-domain cleft (Figure 3) accompanied by its interac-
tions with the enzyme active site and the amino acid resi-
dues from “upper” and “lower” protein domains (Figure 6),
hinder the inter-domain motion and stabilized hDPP III in an
open form (Figure S1 in the supplement).
In line with this is significantly smaller globularity of the
aprotinin complex with hDPP III than of the ligand free-pro-
tein (Rg obtained after 200 ns of MD simulations of com-
plexed protein is about 28.4 Å, while for the ligand-free
protein is about 27.5 Å) (Figure S2 in the supplement).
Further on, binding of aprotinin had no influence on the pro-
tein secondary structure (Table S1 in the supplement) neither
on the 3 D structure of “upper” and “lower” domain
(not shown).
During the whole period of MD simulation of hDPP III-
aprotinin complex the zinc cation was mostly six-coordinated
by two glutamates (Glu451 and Glu508), two histidines
(His450 and His455) and two water molecules (Figure 7). The
zinc cation is coordinated with e nitrogen atoms of H450
and H455 during entire MD simulation (left chart of Figure
S3A in the supplement). Initial bidendate coordination (first
60 ns of simulations) of the zinc cation by Glu451 and
Glu508 changed during the simulation to monodentate, with
OE1 and OE2 atoms exchanging in the metal coordination
(left chart of Figures S3B and C in the supplement). Six-coor-
dinated zinc cation has also been observed during MD simu-
lations of hDPP III in complex with inhibitor (benzimidazole
derivative) (Rastija et al., 2015) and the ligand-free hDPP III
(Tomic et al., 2012). Although the residues Tyr10 to Pro13,
and Arg39 of aprotinin are in the vicinity of the catalytic zinc
ion (minimal distance of 4.7 Å, measured between the zinc
cation and hydroxyl group of Tyr10) (Figure 7), results of MD
simulations imply that the binding of aprotinin into the
enzyme active site has no significant effect on the zinc ion
coordination compared to the zinc ion coordination of lig-
and-free hDPP III (for comparison see left and right charts of
Figures S3 A–C in the supplement). This is also confirmed by
the rmsd analyses of Zn2þ and its coordination sphere for
both ligand-free and complex that is given in Figure 8.
3.4. Analysis of protein–protein interactions
Analysis of protein–protein interactions during MD simula-
tions has revealed that hDPP III-aprotinin complex is mainly
stabilized by H-bonds and hydrophobic interactions.
Hydrogen bonding mostly engaged Lys15 and Arg17
from the aprotinin binding epitope (important for inhibi-
tory function with serine endopeptidases) with amino acid
residues that are constituents of human DPP III S1, S1’, S2,
S2’ and S3’ substrate binding subsites (Bezerra et al., 2012;
Kumar et al., 2016), and with Ser101 and Ser384 (Table 1
and Figure 6). In addition, hydrogen bonding between
Arg39 from aprotinin and Asn406 which is not part of any
of the hDPP III substrate binding subsites, significantly
contributed to ligand stabilization. Aprotinin (mainly by
Ile19, Arg20, Gly37 and Lys46) participates in hydrogen
bonding with residues from the enzyme S1 and S2 sub-
sites, part of which is Tyr318, a functionally important and
evolutionary conserved residue in M49 family (Salopek-
Sondi et al., 2008; Tomic et al., 2011). It is important to
notice that free N-terminus of aprotinin is not bound in
the enzyme S2 subsite, like it is the case with a true hDPP
III substrates (Kumar et al., 2016), which explains the lack
of enzymatic cleavage.
Furthermore, formation of the Arg17-Ser384 and Lys46-
Asn394, aprotinin-enzyme, H-bonds is accompanied by for-
mation of the intramolecular Ser384-Glu327 and Asn394-
Phe314H-bonds (Figure 6 and left chart of Figure S4A and B
in the supplement). Formation of these bonds is also con-
firmed by radial distribution function (RDF) analyses shown
on the right chart of Figure S4A and B, that has very well
defined maximums below 2 Å. These interactions probably
Figure 7. The zinc coordination and the close aprotinin residues in the struc-
ture obtained after 200 ns of MD simulations of the hDPP III complex with apro-
tinin. The zinc cation is presented as a sphere, while dashed lines represent
zinc coordination with electron donors.
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have an effect on aprotinin stabilization in the enzyme bind-
ing site during MD simulations.
Besides by hydrogen bonding, aprotinin molecule is stabi-
lized in the enzyme interdomain cleft by numerous hydro-
phobic interactions that it makes with residues that are also
part of the hDPP III substrate binding subsites: Tyr10-Ser504,
Gly12-His568, Cys14-Ala388, Arg17-Ile386, Ile18-Glu316 and
Gly36-Pro387 (written as aprotinin-hDPP III hydrophobic
interactions of amino acid residues pair, respectively). Finally,
aprotinin backbone rmsd profile also indicates its stability
during the productive MD simulations (Figure 5).
Figure 8. Rmsd profiles of the Zn2þ and its coordination sphere obtained from MD simulations of ligand-free hDPP III and hDPP III-aprotinin complex.
Figure 9. Electrostatic potential surfaces, calculated by the APBS module as
implemented in PyMol: A) of the enzyme molecule extracted from the initial
complex structure and the structures obtained after 2 and 200 ns of MD simula-
tions (aprotinin is shown in cartoon representation), B) of the aprotinin mol-
ecule extracted from the structure of the complex obtained after 200 ns of MD
simulation (hDPP III is shown in cartoon representation, two different views are
given), and C) of the hDPP III-aprotinin complex, structure obtained after 200 ns
of MD simulations (on the right image aprotinin is shown in cartoon represen-
tation to enable better view of the electrostatic potential surface of the enzyme
molecule). The ion concentration, positive (radius 2.0 Å) and negative (radius
1.8 Å), was 0.05 M, and the protein and solvent (radius 1.4 Å) dielectric con-
stants were set to 2 and 78, respectively. Figures are made by program PyMol.
Figure 10. Positively charged amino acids of aprotinin Arg39, Lys41 and Lys46
form electrostatic interactions (dashed lines) with hDPP III residues Asp372,
Asp496 and Asp396, respectively. Optimized structure obtained after 140 ns of
MD simulations was used as a reference structure for displaying electrostatic
interactions.
Table 2. Solvent accessible surface area (SASA) determined by the programs
Naccess version 2.1.1.1 using a probe with the same radius as water (1.4 Å).
DSASA(complex200ns-
complexstart) DSASA(complex2ns-complexstart)
Contribution All Enzyme Aprotinin All Enzyme Aprotinin
All-atoms 1020.11 927.4 92.71 1352.31 1415.62 63.31
Side-chain 850.22 793.75 56.47 1187.19 1313.92 126.73
Main-chain 170 133.79 36.21 164.97 101.62 63.35
Non-polar 96.36 153.72 57.36 241.99 411.69 169.7
Polar 923.89 773.85 150.04 1110.49 1004.12 106.37
Differences with regard to the initial complex structure (starting complex
structure used for molecular modeling study) are shown. Beside DSASA val-
ues for the complex (ALL), we also show DSASA values obtained only for
enzyme or aprotinin residues.
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In our study, for the first time, the protein–protein inter-
action of human DPP III involving the substrate binding
region of this enzyme has been demonstrated. Up to date,
only hDPP III interaction with the Keap1 protein (Gundic
et al., 2016; Hast et al., 2013) has been described. DPP III
binds to Kealch domain of Keap1 via the E480TGE483 motif
situated in the flexible loop on the surface of the “upper”
domain and remote from the substrate binding site.
3.5. Electrostatic potential surface and solvent
accessible surface area
Strong electrostatic stabilization of the positively charged
aprotinin (composed of 4 lysine and 6 arginine residues) with
the negatively charged residues, mostly from the hDPP III
“lower” domain, is clearly demonstrated by visualization of the
electrostatic potential surface calculated by the Adaptive
Poisson–Boltzmann Solver (APBS) (Baker, Sept, Joseph, Holst,
& McCammon, 2001) module implemented in the program
PyMol (Figure 9(A,B)). Electrostatic potential calculated solely
for the enzyme molecule extracted from the initial hDPP III-
aprotinin complex indicates that the most favorable polypep-
tide binding mode was predicted to be the one where posi-
tively charged aprotinin molecule is situated just above
negatively charged protein region next to the five-stranded
b-core of the DPP III “lower” domain (Figure 9(A)), while nega-
tively charged aprotinin residues close to its C and N-terminus
are sticking outside of the protein interdomain cleft into the
bulk (Figure 9(B,C)). The electrostatic potential surface calcula-
tions performed on the enzyme structures obtained during
MD simulations of the hDPP III-aprotinin complex revealed
that the enzyme binding cleft adjusted to the positively
charged aprotinin and became even more negatively charged
(structures sampled at 2nd and 200th ns of MD simulation,
Figure 9(A)) than in the initial structure. Apparently, the polar
protein residues in the binding site reoriented in a way to
establish more interactions with aprotinin.
The most important intermolecular electrostatic interac-
tions formed during the MD simulations were Arg39-Asp372,
Lys41-Asp496 and Lys46-Asp396 (written as aprotinin-hDPP
III amino acid pair, respectively) (Figure 10 and left side of
the Supplemental Figure S5 A–C). The bonds existence is
confirmed by RDF analyses (right side of the Supplemental
Figure S5A–C), where all the maximums are below 3 Å . This
finding on important electrostatic interaction of Asp496 with
aprotinin is in agreement with the recently reported results
of mutational analysis which have shown that replacement
of Asp496 with Gly lowered binding potency for aprotinin by
12.7-fold, compared to the wild-type hDPP III (Abramic et al.,
2015) indicating the important role of Asp496 in the hDPP III
substrate specificity.
Table 3. Intermolecular interactions between selected enzymes and aprotinin amino acid residues.
Aprotinin
interaction
residues DPP III (3FVY) Trypsin (2PTC)
Chymotrypsin
(1CBW)
Dengue virus NS3
protease (3U1J) Kallikrein (2KAI) Thrombin (1BTH) Prostasin (3GYM)
Matriptase
(1EAW)
ASP3 HB – – – – – – –
GLU7 HI – – – – – – –
PRO8 HB, HI – – – – – – –
TYR10 HI – – – – – HB –
THR11 HI – – HI HI HI HI
GLY12 HB, HI HI – HI – – –
PRO13 HI HB HB HB HB HB HB, HI HB
CYS14 HI HB HI HB HI HB HI HB
LYS15 HB HB HB HB HB HB HB HB
ALA16 HI HI HI HI HI HI HI HB, HI
ARG17 HB, HI HB HB, HI HB HB, HI HB HB, HI HB
ILE18 HB, HI – – – HI HI – HI
ILE19 HB, HI HB – HI – HI –
ARG20 HB – – – – HB, HI – HB, HI
TYR21 – – – HI – – – –
LYS26 HB, HI – – – – – – –
ALA27 – – HI – – – – –
GLY28 – – HI – – – – –
THR32 – HI HI – –
VAL34 – HI HI HB – HI
TYR35 – – HI
GLY36 HB, HI – – – HI – – HI
GLY37 HB HI HI HI HI HI HI –
CYS38 HI HI HI HI HI
ARG39 HB HB HI – HB HB HB HB
LYS41 – – – – – HI – HB
ARG42 HB – – – – HI – –
ASN43 – – – – – HB – –
ASN44 – – – – – – – HB
LYS46 HB – – HB – HI HI HI
SER47 HB, HI – – – – – – –
GLU49 – – HI – – – – –
MET52 – – HI – – – – –
ARG53 – – HI – – – – –
Data used for DPP III, trypsin, chymotrypsin, Dengue virus NS3 protease, kallikrein, thrombin, prostasin and matriptase was obtained from the
LigPlotþ diagrams for PDB codes 3FVY, 2PTC, 1CBW, 3U1J, 2KAI, 1BTH, 3GYM and 1EAW respectively. Optimized 3FVY-aprotinin complex obtained after
200 ns of MD simulations. HB and HI are the abbreviations of hydrogen bond and hydrophobic interaction, respectively.
JOURNAL OF BIOMOLECULAR STRUCTURE AND DYNAMICS 3603
In addition, we calculated differences in the solvent
accessible surface area (SASA) by program Naccess (Naccess
version 2.1.1, Faculty of Life Sciences, The University of
Manchester, Manchester, UK) (Lee & Richards, 1971) and
showed that the initial complex structure used for molecular
modeling study has the largest SASA (Table 2). The structure
obtained after 2 ns of MD simulation has smaller SASA than
the structure obtained after 200 ns of MD simulation mostly
as a result of enzyme side chains being less exposed to
water. At the same time, aprotinin molecule seems to be less
water exposed in the complex structure obtained after
200 ns of MD simulations, then in the one obtained after 2 ns
of MD simulations. This is also mostly due to the aprotinin
side chain reorientation, probably in order to establish more
favorable electrostatic interactions with protein interdo-
main cleft.
3.6. Comparison of the aprotinin binding mode in hDPP
III with those in the selected serine peptidases
Aprotinin inhibits many serine peptidases, among them and
those of viral origin (Mueller, Yon, Ganesh, & Padmanabhan,
2007; Noble, She, Chao, & Shi, 2012). By analyzing the avail-
able crystal structures of the aprotinin-serine peptidase com-
plexes we were able to compare the protein–protein
intermolecular interactions with those found in the hDPP III-
aprotinin complex. Table 3 illustrates that aprotinin residues
13(Pro) to 17(Arg) interact with all examined peptidases
through hydrophobic or H-bond interactions, or both. Amino
acids Gly37 to Arg39 are also frequently used in aprotinin
contacts with peptidases. Our study on hDPP III has shown
several additional interactions, not found in other complexes,
outside canonical binding epitope. Those are interactions
with amino acids near the N-terminus Asp3, Glu7 and Pro8,
and with Lys26 and Ser47 (Table 3).
4. Conclusions
In this study, a combined experimental and computational
approach was used for investigation of the interaction
between the human DPP III, metallopeptidase of the family
M49 and aprotinin, polypeptide inhibitor of serine protei-
nases. Incubation with high concentration of enzyme, fol-
lowed by MALDI-TOF MS analysis did not show degradation
of aprotinin.
Docking of aprotinin into the region of inter-domain cleft
of hDPP III and long MD simulations of the enzyme-inhibitor
complex revealed that this compact polypeptide interacts
with the substrate binding cleft of hDPP III by its canonical
binding loop (binding epitope), whereby, the free N-terminus
of aprotinin (Arg-Pro-Asp-Phe) is positioned distant from the
enzyme active-site, which explains absence of the enzym-
atic cleavage.
MD simulations suggest that enzyme-inhibitor complex is
stabilized by hydrogen bonding, electrostatic and hydropho-
bic interactions mostly with amino acid residues of the
human DPP III S1, S1’, S2, S2’ and S3’substrate binding
subsites. To our knowledge, this is the first report on inter-
action details of aprotinin with a metallopeptidase.
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